Moreover, longitudinal measurements of the proportion of ILCs based on the clinical course of the disease after initiating anti-IL-17A therapy may be helpful for understanding ILC differentiation in the context of blocking IL-17A in Crohn’s disease. This evidence concerns the gene IL17A and Crohn disease.